Analysts Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) PT at $61.90

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has been assigned an average recommendation of "Hold" from the twelve brokerages that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $61.90.

HALO has been the topic of several recent analyst reports. Morgan Stanley downgraded Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their target price for the company from $73.00 to $62.00 in a research note on Wednesday, May 14th. Wells Fargo & Company lifted their price objective on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research report on Wednesday, May 7th. HC Wainwright reissued a "buy" rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a report on Thursday, May 29th. JPMorgan Chase & Co. upped their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Finally, Benchmark cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th.

Halozyme Therapeutics Stock Performance

NASDAQ HALO traded down $0.56 on Thursday, reaching $53.98. 1,218,546 shares of the stock were exchanged, compared to its average volume of 1,634,157. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics has a one year low of $42.01 and a one year high of $70.51. The firm has a market capitalization of $6.65 billion, a PE ratio of 15.74, a PEG ratio of 0.42 and a beta of 1.19. The company's 50-day simple moving average is $57.34 and its two-hundred day simple moving average is $56.13.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $264.86 million for the quarter, compared to analysts' expectations of $231.21 million. During the same quarter in the previous year, the company earned $0.79 EPS. Halozyme Therapeutics's revenue for the quarter was up 35.2% on a year-over-year basis. Analysts expect that Halozyme Therapeutics will post 4.73 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 4,497 shares of Halozyme Therapeutics stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $60.37, for a total value of $271,483.89. Following the completion of the transaction, the director now owns 28,611 shares in the company, valued at approximately $1,727,246.07. This trade represents a 13.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 2.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Several institutional investors have recently modified their holdings of HALO. Venturi Wealth Management LLC purchased a new stake in Halozyme Therapeutics during the 4th quarter valued at $69,000. D. E. Shaw & Co. Inc. increased its position in Halozyme Therapeutics by 171.2% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock valued at $39,750,000 after acquiring an additional 524,802 shares during the last quarter. Davidson Capital Management Inc. increased its position in Halozyme Therapeutics by 111.2% during the fourth quarter. Davidson Capital Management Inc. now owns 56,639 shares of the biopharmaceutical company's stock valued at $2,708,000 after acquiring an additional 29,826 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Halozyme Therapeutics by 0.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company's stock valued at $85,254,000 after acquiring an additional 9,780 shares during the period. Finally, Rhumbline Advisers lifted its holdings in shares of Halozyme Therapeutics by 1.4% in the 4th quarter. Rhumbline Advisers now owns 410,508 shares of the biopharmaceutical company's stock worth $19,626,000 after acquiring an additional 5,833 shares during the last quarter. 97.79% of the stock is owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.